

ABSTRACT SUBMISSION FORM

LET'S TALK ABOUT

SEX + GENDER

Exploring the role of sex and gender on health research



CHR D 2020: Abstract Submission Form

Submitter Name

Mira Villegas

Email

villegam@myumanitoba.ca

Title

Characterization of Fistulizing Perianal Crohn's Disease in Children

Background

Inflammatory bowel disease (IBD) is a chronic, incurable gastrointestinal disease. In Manitoba, the incidence and prevalence of IBD in children has increased over the last few decades. Pediatric IBD affects children and adolescents, with up to 25% of all patients diagnosed with Crohn's disease (CD) presenting before the age of 20 years old. CD with perianal involvement is associated with significant morbidity, rapid progression of the disease, and poorer outcomes.

Objective

To characterize pediatric patients in Manitoba diagnosed with fistulizing perianal CD (PCD) and compare them to patients diagnosed with CD without perianal disease.

Methods

This cohort included all children and adolescents (0-17 years old) diagnosed with CD at the Children's Hospital of Winnipeg from January 2012 to June 2020. Variables examined include, demographics, symptoms at presentation, laboratory values, magnetic resonance (MR) findings, Pediatric Crohn Disease Activity Index (PCDAI), and EuroQol 5-dimension 5-level (EQ5D5L) scores. Categorical variables were reported as frequency distributions, with 95% confidence intervals (CIs) for means and proportions. Univariate summaries were obtained for continuous variables. All statistical tests were two-tailed with the level of significance set as $p < 0.05$.

Results

Data were available for 19 patients diagnosed with fistulizing PCD (10 [52.6%] female, 9 [47.4%] male). The most common symptoms presented at diagnosis were abdominal pain (63.2%), diarrhea (57.9%), bleeding rectum (57.9%), weight loss (57.9%), and perianal discharge (52.9%). Family history of IBD, in a first or second degree relative, was reported in 31.6% of patients. PCD patients were compared to patients diagnosed with CD without perianal disease, (26 [46.4%] female, 30 [53.6%] male), as seen in Table 1.

Magnetic resonance enterography (MRE) results were also compared.

Conclusion

Perianal Crohn's disease is a serious complication of Crohn's disease. The results of our study will help improve our understanding of fistulizing PCD in the pediatric population.

Theme:

Clinical

Do you have a table/figure to upload?

Yes

Untitled

CHRD Table I PCD 2020.pdf

Are you willing to participate in Goodbear's Den?

Yes

Presenter Status:

Undergraduate Students

What was your role in the project?

Collect Data, Perform Data Analysis, Write Abstract

Authors

Name	Email	Role	Profession
Mira Villegas	villegam@myumanitoba.ca	Presenting Author	Undergraduate Student
Dr. Wael El-Matary	welmatary@hsc.mb.ca	Co Author	Full Professor
Dr. Jens Wrogemann		Co Author	Lecturer

TABLE I. Cohort Characteristics of Pediatric Patients Diagnosed with Fistulizing Perianal Crohn's Disease Compared to Patients Diagnosed with Crohn's Disease without Perianal Disease

	PCD Patients n = 19	CD Patients n = 56	p-value
Gender			0.79
Male	9	30	
Female	10	26	
Age at Diagnosis (Years) Median (IQR)	13.5 (11.4-15.3)	13.6 (11.0-15.0)	0.70
Duration of Symptoms Prior to Diagnosis (Months) Median (IQR)	6.0 (3.0-12.0)	3.0 (2.0-10.0)	0.29
Hemoglobin at presentation (g/L) Mean \pm SD	107.3 \pm 15.5	111.0 \pm 13.4	0.47
Albumin at presentation (g/L) Mean \pm SD	30.8 \pm 6.3	31.9 \pm 6.8	0.56
ESR at presentation (mm/hr) Mean \pm SD	51.1 \pm 30.7	40.2 \pm 24.5	0.21
CRP at presentation (mg/L) Mean \pm SD	46.1 \pm 66.0	28.4 \pm 36.3	0.40
PCDAI at Diagnosis Mean \pm SD	27.9 \pm 18.2	26.4 \pm 17.6	0.82
EQ5D5L Score at Diagnosis Mean \pm SD	80.3 \pm 18.9	75.4 \pm 16.0	0.46
PCDAI at Final Follow-Up Mean \pm SD	4.7 \pm 7.7	4.5 \pm 7.3	0.98
EQ5D5L Score at Final Follow-Up Mean \pm SD	90.8 \pm 9.9	92.0 \pm 10.4	0.54
Duration of Follow-Up (Years) Median (IQR)	1.8 (1.2-2.2)	2.9 (1.2-3.8)	0.02

ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PCDAI, Pediatric Crohn Disease Activity Index; EQ5D5L, EuroQol 5-Dimension 5-Level